NCT00511602已完成2 期
Efficacy and Safety of Inhaled Technosphere Insulin Compared to Technosphere Placebo in Patients With Type 2 Diabetes Mellitus Following Diabetes Education
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 123
- 主要终点
- HbA1c change from baseline (week 2) to end of treatment (week 12)
研究概览
简要总结
Primary objective to evaluate the effect of a 12-week treatment period with prandial administration of Technosphere Insulin on glucose control in subjects with T2 DM. Secondary objective is to Evaluate the safety and tolerability of a 12-week treatment period of Technosphere Insulin and Technosphere Placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of T2 DM of >2 years and <12 years duration
- •Insulin treatment naive treated with diet/exercise or single/combination oral anti-diabetic agents, such as metformin, sulfonylurea, and/or thiazolidinediones
- •Stable regimen for >3 months of oral anti-diabetes medication prior to enrollment
- •HbA1c >6.6% and <10.5%
- •BMI <38 kg/m2
- •18-80 years of age
- •Baseline FVC and FEV1 >80% and <120% of predicted normal as measured by spirometry
- •Baseline DLCO >80% and <120% of predicted normal
排除标准
- •Clinical diagnosis of type 1 diabetes mellitus
- •Subjects currently using insulin therapy or at the time of screening
- •Known hypersensitivity to the study drug or to drugs of similar chemical structures
- •Fasting plasma glucose >270 mg/dL without adequate explanation of a transient causality (screen could be repeated after a 2-week interim period)
- •History of severe or multiple allergies
- •History of tobacco or nicotine test at screening
- •Severe complications of diabetes including history of blindness from or Stage III or IV diabetic retinopathy, history of renal failure requiring dialysis or transplantation, history of amputation of limbs or digits related to diabetic vasculopathy
- •Treatment with another investigational drug within 3 months prior to study entry (and for the duration of the study)
- •Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled steroids, beta blockers, with the exception of beta blocker ophthalmic solutions for glaucoma or ocular hypertension, or hydrochlorothiazide (HCTZ) at doses >25 mg/day
- •Recent loss (within the 2 months prior to screening) of >5% of body weight
- •Evidence of moderate or greater ketones in urine or ketoacidosis at screening
- •History of chronic obstructive pulmonary disease or history of other known chronic pulmonary disease such as reactive airway disease, chronic bronchitis, emphysema, or asthma
- •Diagnosis of AIDS or ARC
- •A major psychiatric disorder that would have precluded satisfactory participation in this study
- •Subjects who had had a myocardial infarction or stroke within the preceding six months
- •Prior diagnosis of systemic autoimmune or collagen vascular disease requiring heart disease graded as Class III or Class IV according to New York Heart Association criteria
- •Prior treatment with, or participation in, a clinical study involving an inhaled insulin product
- •History of malignancy within 5 years of study entry (other than basal cell carcinoma)
- •Significant hepatic disease (as evidenced by ALT or AST >3 times the reference normal range or bilirubin >1.5 times the reference normal range)
- •Significant renal disease (as evidenced by creatinine >1.5 mg/dL for males or >1.3 mg/dL for females), proteinuria as evidenced by greater than "small" by dipstick measurement or >2 grams in 24 hours, dialysis, or history of renal transplant
- •History of previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine
研究组 & 干预措施
Technosphere Insulin Inhalation Powder
Experimental
干预措施: Technosphere Insulin (Drug)
Technosphere Inhalation Powder
Placebo Comparator
干预措施: Technosphere Placebo (Drug)
结局指标
主要结局
HbA1c change from baseline (week 2) to end of treatment (week 12)
时间窗: 12 weeks
次要结局
- Area under the plasma glucose concentration versus time (AUCglucose)(every 4 weeks)
- Maximum glucose concentration (Cmax)(every 4 weeks)
- Time to maximum glucose concentration (tmax)(every 4 weeks)
- Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations(every 2 weeks)
研究者
相似试验
终止
3 期
Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and AsthmaDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2AsthmaNCT00332826Mannkind Corporation3
终止
3 期
Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.Non Cystic Fibrosis BronchiectasisNCT03460704Zambon SpA287
终止
2 期
Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate IntakeDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT00747006Mannkind Corporation18
招募中
3 期
Efficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in hospitalized Covid-19 patientsCOVID-19.COVID-19, virus identifiedU07.1IRCT20200511047396N1CinnaGen company50
已完成
3 期
To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of AirwaysPulmonary Disease, Chronic ObstructiveNCT02085161Boehringer Ingelheim304